Journal of Multidisciplinary Applied Natural Science
##plugins.themes.gdThemes.journalSlogan##
Scopus CiteScore 2024
4.8
Calculated on 05 May, 2025
SJR 2024
0.31
Powered by scimagojr.com
##plugins.themes.gdThemes.journalSlogan##
4.8
Calculated on 05 May, 2025
0.31
Powered by scimagojr.com
https://doi.org/10.47352/jmans.2774-3047.370
Nita Sahara
Ambar Mudigdo
Brian Wasita
Eti Poncorini Pamungkasari
Paramasari Dirgahayu
Risya Cilmiaty
Benign prostatic hyperplasia (BPH) progression is critically influenced by the androgen receptor (AR), Fibroblast growth factor-2 (FGF-2), and transforming growth factor-β (TGF-β) signaling axis. Although finasteride (FIN) is the standard therapeutic agent, its use is limited by adverse effects. This study evaluated the efficacy of Cosmos caudatus (CC) extract, administered alone or in combination with FIN, in modulating the AR–FGF-2–TGF-β axis in a testosterone-induced BPH rat model. Rats were divided into five groups (n = 6): Normal (N), BPH control (KN), FIN (KP; 0.44 mg/kg), CC extract (P1; 250 mg/kg), and combination (P2; CC 250 mg/kg + FIN 0.44 mg/kg). Prostatic AR, FGF-2, and TGF-β expression was analyzed using immunohistochemistry (IHC) with H-score quantification. Both KP and P1 significantly reduced AR (KP: 112 ± 15; P1: 105 ± 12 vs KN: 195 ± 18, p < 0.05) and FGF-2 (KP: 98 ± 14; P1: 92 ± 11 vs KN: 180 ± 20, p < 0.05), approaching normal values (AR N: 90 ± 10; FGF-2 N: 85 ± 9). In contrast, combination therapy (P2) failed to suppress AR (188 ± 17, p = 0.936) and FGF-2 (175 ± 19, p = 0.870) and induced a significant increase in TGF-β (P2: 145 ± 16 vs KN: 110 ± 12, p < 0.05). All treatment groups showed reduced epithelial thickness and prostate index (p < 0.05). These findings indicate that CC extract alone exerts therapeutic effects comparable to FIN by modulating the AR–FGF-2 axis, whereas combining it with FIN disrupts pathway regulation and promotes a pro-fibrotic response. The study supports the potential of CC extract as an effective alternative for BPH management without pharmacologic complications.
[1] R. E. Vickman, O. E. Franco, D. C. Moline, D. J. Vander Griend, P. Thumbikat, and S. W. Hayward. (2020). "The Role of the Androgen Receptor in Prostate Development and Benign Prostatic Hyperplasia: A Review". Asian Journal of Urology. 7 (3): 191-202. 10.1016/j.ajur.2019.10.003.
[2] J. C. Nickel, C. G. Roehrborn, R. Castro-Santamaria, S. J. Freedland, and D. M. Moreira. (2016). "Chronic Prostate Inflammation Is Associated With Severity and Progression of Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms and Risk of Acute Urinary Retention". The Journal of Urology. 196 (5): 1493-1498. 10.1016/j.juro.2016.06.090.
[3] K. B. Lim. (2017). "Epidemiology of Clinical Benign Prostatic Hyperplasia". Asian Journal of Urology. 4 (3): 148-151. 10.1016/j.ajur.2017.06.004.
[4] R. Shukla, V. Pandey, G. P. Vadnere, and S. Lodhi. (2019). In: "Bioactive Food as Dietary Interventions for Arthritis and Related Inflammatory Diseases (Second Edition)". Elsevier. 10.1016/B978-0-12-813820-5.00018-0.
[5] O. Edirisinghe, G. Ternier, Z. Alraawi, and T. K. Suresh Kumar. (2024). "Decoding FGF/FGFR Signaling: Insights into Biological Functions and Disease Relevance". Biomolecules. 14 (12. 10.3390/biom14121622.
[6] G. Lee, H. Lee, L. Zhao, M. M. U. Rashid, M. K. Kim, Y. B. Jeong, H. Chae, and Y. S. Shin. (2023). "The Role of Reactive Oxygen Species, Inflammation, and Endoplasmic Reticulum Stress Response in the Finasteride Protective Effect Against Benign Prostate Hyperplasia". World Journal of Men's Health. 41 (3): 600-609. 10.5534/wjmh.230122.
[7] H. Zhang, L. Yang, Q. Han, and W. Xu. (2022). "Antifibrotic Effects of Quercetin on TGF-β1-Induced Vocal Fold Fibroblasts". American Journal of Translational Research. 14 (12): 8552-8561.
[8] S. Ghafouri-Fard, F. A. Shabestari, S. Vaezi, A. Abak, H. Shoorei, A. Karimi, M. Taheri, and A. Basiri. (2021). "Emerging Impact of Quercetin in the Treatment of Prostate Cancer". Biomedicine and Pharmacotherapy. 138 : 111548. 10.1016/j.biopha.2021.111548.
[9] M. Rafi, F. Hayati, A. H. Umar, D. A. Septaningsih, and T. Rachmatiah. (2023). "LC-HRMS-Based Metabolomics to Evaluate the Phytochemical Profile and Antioxidant Capacity of Cosmos Caudatus With Different Extraction Methods and Solvents". Arabian Journal of Chemistry. 16 (9): 105065. 10.1016/j.arabjc.2023.105065.
[10] W. Fu, S. Chen, Z. Zhang, Y. Chen, X. You, and Q. Li. (2022). "Quercetin in Tonglong Qibi Decoction Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia in Rats by Regulating Nrf2 Signalling Pathways and Oxidative Stress". Andrologia. 54 (9). 10.1111/and.14502.
[11] M. J. Lee, Y. Cho, Y. Hwang, Y. Jo, Y. Kim, S. H. Lee, and J. H. Lee. (2023). "Kaempferol Alleviates Mitochondrial Damage by Reducing Mitochondrial Reactive Oxygen Species Production in Lipopolysaccharide-Induced Prostate Organoids". Foods. 12 (20). 10.3390/foods12203836.
[12] R. W. Azzahra, N. Murdaya, A. A. Al Shofwan, E. Ramadan, and S. D. Utami. (2021). "Molecular Docking Senyawa Ekstrak Etanol Daun Kenikir (Cosmos Caudatus) Sebagai Inhibitor IL-6 Dalam Respon Inflamasi". Jurnal Farmasi Udayana. 10 (2): 138. 10.24843/JFU.2021.v10.i02.p05.
[13] B. R. Jin, H. J. Kim, J. H. Na, W. K. Lee, and H. J. An. (2024). "Targeting Benign Prostate Hyperplasia Treatments: AR/TGF-β/NOX4 Inhibition by Apocynin Suppresses Inflammation and Proliferation". Journal of Advanced Research. 57 : 135-147. 10.1016/j.jare.2023.04.006.
[14] A. Almatroudi, K. S. Allemailem, W. M. Alwanian, B. F. Alharbi, F. Alrumaihi, A. A. Khan, S. A. Almatroodi, and A. H. Rahmani. (2023). "Effects and Mechanisms of Kaempferol in the Management of Cancers Through Modulation of Inflammation and Signal Transduction Pathways". International Journal of Molecular Sciences. 24 (10). 10.3390/ijms24108630.
[15] Z. K. Tuong, K. W. Loudon, B. Berry, N. Richoz, J. Jones, X. Tan, Q. Nguyen, A. George, S. Hori, S. Field, A. G. Lynch, K. Kania, P. Coupland, A. Babbage, R. Grenfell, T. Barrett, A. Y. Warren, V. Gnanapragasam, C. Massie, and M. R. Clatworthy. (2021). "Resolving the Immune Landscape of Human Prostate at a Single-Cell Level in Health and Cancer". Cell Reports. 37 (12): 110132. 10.1016/j.celrep.2021.110132.
[16] D. Daud, N. F. Mohd Fekery, and N. Hashim. (2017). "Reproductive Health of Rats with Benign Prostatic Hyperplasia Following Cosmos Caudatus Ethanolic Extract Consumption". Journal of Applied Pharmaceutical Science. 7 (6): 202-205. 10.7324/JAPS.2017.70630.
[17] S. M. Lee, S. M. Lee, and J. Song. (2024). "Effects of Taraxaci Herba (Dandelion) on Testosterone Propionate-Induced Benign Prostatic Hyperplasia in Rats". Nutrients. 16 (8). 10.3390/nu16081189.
[18] S. Wang, Y. Li, W. Li, K. Zhang, Z. Yuan, Y. Cai, K. Xu, J. Zhou, and Z. Du. (2021). "Curcuma Oil Ameliorates Benign Prostatic Hyperplasia Through Suppression of the Nuclear Factor-Kappa B Signaling Pathway in Rats". Journal of Ethnopharmacology. 279 : 113703. 10.1016/j.jep.2020.113703.
[19] D. Nguyen, P. Herzog, E. B. Cone, M. Labban, K. C. Zorn, B. Chughtai, S. Basaria, D. S. Elterman, Q. Trinh, and N. Bhojani. (2023). "Disproportional Signal of Sexual Dysfunction Reports Associated with Finasteride Use in Young Men with Androgenetic Alopecia: A Pharmacovigilance Analysis of VigiBase". Journal of the American Academy of Dermatology. 88 (1): 179-181. 10.1016/j.jaad.2022.03.037.
[20] S. Madersbacher, N. Sampson, and Z. Culig. (2019). "Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review". Gerontology. 65 (5): 458-464. 10.1159/000496289.
[21] P. J. Espitia-Perez, L. M. Espitia-Perez, and M. Negrette-Guzman. (2025). "Targeting Prostate Cancer Metabolism Through Transcriptional and Epigenetic Modulation: A Multi-Target Approach to Therapeutic Innovation". International Journal of Molecular Sciences. 26 (13). 10.3390/ijms26136013.
[22] X. Wang, J. Zhu, H. Yan, M. Shi, Q. Zheng, Y. Wang, Y. Zhu, L. Miao, and X. Gao. (2021). "Kaempferol Inhibits Benign Prostatic Hyperplasia by Resisting the Action of Androgen". European Journal of Pharmacology. 893 : 173852. 10.1016/j.ejphar.2021.174251.
[23] L. V. Stewart and E. D. Lephart. (2023). "Androgen, Inflammation, and Growth Factor Interactions in the Progression of Benign Prostatic Hyperplasia". Andrology. 11 (2): 215-227. 10.1111/andr.13345.
[24] A. Khan, H. A. Alzahrani, S. G. Felemban, A. S. Algarni, A. B. S. Alenezi, M. Kamal, Z. U. Rehman, S. M. B. Asdaq, N. Ahmed, B. M. Alharbi, B. S. Alanazi, and M. Imran. (2025). "Exploring TGF-beta signaling in benign prostatic hyperplasia: from cellular senescence to fibrosis and therapeutic implications". Biogerontology. 26 (2): 79. 10.1007/s10522-025-10226-x.
[25] S. Halder, G. Brahmachari, and K. Jana. (2025). In: "Discovery and Development of Anti-Prostate Cancerous Agents from Natural Products". 9-35. 10.1016/b978-0-443-21842-2.00002-4.
